StockTipsArenaBeta

BUY Glenmark Pharmaceuticals — Somil Mehta, Sharekhan

BUYGlenmark Pharmaceuticals
Glenmark Pharmaceuticals share price target & all analyst calls

bySomil Mehta, SharekhanHorizon: NA (inferred Swing (≤2wk))23 Jun 2026via CNBC Awaaz.

Entry₹2,221.2Inferred
Target₹2,300
Total upside +3.55% (call closed)
Stop loss₹2,160-2.76% risk
Exit₹2,16024 Jun 2026, 11:30 am
Stop-loss hit-2.76%
Follow Somil Mehta for new calls(22% target hit, 249 closed calls)Get alertsWatch GLENMARK for new buy/sell callsGet alertsSee 2 active Swing calls on GLENMARKSee 108 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 22 Oct, 8:29 am IST
2 supporting0 opposing
Supports the BUY call (2)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·23 Jun · yesterday

Glenmark Pharmaceuticals Inc., USA launched Methylene Blue Injection USP, potentially increasing revenue.

BSE · Company Update·17 Jun · 1w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (0)

Nothing found in this tip’s window yet.

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Glenmark Pharmaceuticals

All analyst calls on Glenmark Pharmaceuticals

More from Somil Mehta, Sharekhan

Every call and its outcome